While AI dominates headlines, GLP-1s offer more immediate and tangible improvements to human health and quality of life. The market impact of solving pervasive health crises like obesity, addiction, and heart disease may ultimately dwarf the current perceived value of AI.

The impact of GLP-1 medications like Ozempic extends far beyond weight loss. Emerging research shows profoundly positive second-order effects, including halving metastatic cancer growth rates and potentially delaying dementia and Alzheimer's, signaling a massive, unexpected public health revolution.

Eli Lilly’s $6.3B acquisition of a biotech with an orexin (OX2R) agonist is significant. The deal's contingent value rights (CVRs) are tied to indications outside of narcolepsy type 1, signaling big pharma's belief this mechanism has broad potential in larger sleep and neurological disorder markets.

Max Marchione consistently uses the success of GLP-1 agonists (e.g., Ozempic) to counter the claim that peptides are an inferior drug class. By highlighting that perhaps the most impactful drug of the modern era is a peptide, he argues that the entire category holds immense, untapped potential that cannot be dismissed.

The success of GLP-1s like Ozempic, which address weight loss, addiction, and metabolic fitness, has made the public more receptive to longevity drugs. People now better understand how a single drug targeting a core mechanism (like metabolic health) can have widespread, seemingly magical downstream benefits.

Originally for diabetes, GLP-1s' broad positive effects on inflammation, heart, and brain function position them as the first mainstream drugs for human enhancement and longevity, moving beyond simple disease management.

While AI dominates headlines, GLP-1 drugs could have a more profound and immediate impact on society. They address the core mechanism of desire ("wanting less"), with applications for obesity, addiction, and compulsive behaviors that could fundamentally reshape public health and daily life.

When comparing drugs with the same mechanism, like Alkermes' and Takeda's orexin agonists, a wider therapeutic index is a crucial differentiator. This superior safety-to-efficacy ratio allows for higher, more effective dosing without significant side effects, creating a competitive advantage and potential for broader market use.

Takeda's leadership in the competitive orexin space for narcolepsy resulted from a key R&D strategy: they had already begun developing an improved backup compound before their initial Phase 2 candidate showed a toxicity signal. This foresight allowed an immediate pivot, preserving momentum and gaining a competitive edge.